129 related articles for article (PubMed ID: 22185637)
1. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Guisado-Vasco P; Arranz-Saez R; Canales M; Cánovas A; Garcia-Laraña J; García-Sanz R; Lopez A; López JL; Llanos M; Moraleda JM; Rodriguez J; Rayón C; Sabin P; Salar A; Marín-Niebla A; Morente M; Sánchez-Godoy P; Tomás JF; Muriel A; Abraira V; Piris MA; Garcia JF; Montalban C;
Leuk Lymphoma; 2012 May; 53(5):812-9. PubMed ID: 22185637
[TBL] [Abstract][Full Text] [Related]
2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
3. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.
Moccia AA; Donaldson J; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Shenkier TN; Slack GW; Skinnider B; Gascoyne RD; Connors JM; Sehn LH
J Clin Oncol; 2012 Sep; 30(27):3383-8. PubMed ID: 22869887
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
Diefenbach CS; Li H; Hong F; Gordon LI; Fisher RI; Bartlett NL; Crump M; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ; Advani RH
Br J Haematol; 2015 Nov; 171(4):530-8. PubMed ID: 26343802
[TBL] [Abstract][Full Text] [Related]
5. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
Fernandez-Alvarez R; Gonzalez-Rodriguez AP; Gonzalez ME; Rubio-Castro A; Dominguez-Iglesias F; Solano J; Alonso-Nogues E; Fernandez-Alvarez C; Zanabili Y; Alonso JM; Payer AR; Vicente JM; Medina J; Sancho JM
Leuk Lymphoma; 2015; 56(11):3096-102. PubMed ID: 25860241
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
7. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
[TBL] [Abstract][Full Text] [Related]
8. Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma.
Hayden AR; Lee DG; Villa D; Gerrie AS; Scott DW; Slack GW; Sehn LH; Connors JM; Savage KJ
Br J Haematol; 2020 Apr; 189(1):122-127. PubMed ID: 31822034
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era.
Wang Q; Qin Y; Zhou S; He X; Yang J; Kang S; Liu P; Yang S; Zhang C; Gui L; Sun Y; Shi Y
Oncotarget; 2016 Nov; 7(44):72219-72228. PubMed ID: 27750215
[TBL] [Abstract][Full Text] [Related]
10. A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma.
Tao Y; Chen H; Zhou Y; He X; Qin Y; Liu P; Zhou S; Yang J; Zhou L; Zhang C; Yang S; Gui L; Shi Y
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e486-e494. PubMed ID: 35238169
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma.
Ganesan P; Dhanushkodi M; Ganesan TS; Radhakrishnan V; Kannan K; Sundersingh S; Sagar TG
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):116-122. PubMed ID: 30579722
[TBL] [Abstract][Full Text] [Related]
13. Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era.
Wang Q; Qin Y; Kang SY; He XH; Liu P; Yang S; Zhou SY; Zhang CG; Gui L; Yang JL; Sun Y; Shi YK
Chin Med J (Engl); 2016 Dec; 129(23):2780-2785. PubMed ID: 27900988
[TBL] [Abstract][Full Text] [Related]
14. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
[TBL] [Abstract][Full Text] [Related]
15. Comments on the value International Prognostic Score (IPS), stage IV and age over 45 years, for the outcome of advanced Hodgkin lymphoma in chemotherapy containing adriamycin. The experience of the Spanish Hodgkin Lymphoma Study Group.
Guisado-Vasco P; Montalban C; García JF;
Br J Haematol; 2017 Jul; 178(2):336-338. PubMed ID: 27135208
[No Abstract] [Full Text] [Related]
16. IPS-3 Validation in 1012 cases with classical hodgkin lymphoma.
Paydas S; Laçin S; Doğan M; Barista I; Yildiz B; Seydaoglu G; Karadurmus N; Civriz S; Kaplan MA; Yagci M; Gurkan E; Ercolak V
Leuk Res; 2021 Mar; 102():106519. PubMed ID: 33556744
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study.
Batty N; Hagemeister FB; Feng L; Romaguera JE; Rodriguez MA; McLaughlin P; Samaniego F; Copeland A; Dabaja BS; Younes A
Leuk Lymphoma; 2012 May; 53(5):801-6. PubMed ID: 22023528
[TBL] [Abstract][Full Text] [Related]
19. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
Bhethanabhotla S; Jain S; Kapoor G; Mahajan A; Chopra A; Vishnubhatla S; Bakhshi S
Leuk Lymphoma; 2017 Jul; 58(7):1617-1623. PubMed ID: 27919174
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
